Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Clinical and Translational Science
|
June 20, 2022
Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies
Jayaprakasam Bolleddula, Sathej Gopalakrishnan, Ping Hu, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists
|
March 29, 2014
Mesodermal Fgf10b cooperates with other fibroblast growth factors during induction of otic and epibranchial placodes in zebrafish
Kirstin Maulding, Mahesh S Padanad, Jennifer Dong, et al.
Journal of Medical Education and Curricular Development
|
December 30, 2025
Assessing Clinical Integration of Point-of-Care Ultrasound With an Objective Structured Clinical Examination
N Caroline Srisarajivakul-Klein, Jennifer Dong, Aron Mednick, et al.
Cancer Chemotherapy and Pharmacology
|
June 30, 2022
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
Wenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, et al.
Clinical and Translational Science
|
October 24, 2024
Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler
Hong Lu, Lena Klopp-Schulze, Jatinder Kaur Mukker, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
October 26, 2023
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective
Holger Scheible, Hanno Schieferstein, Ralf Schmidt, et al.
Clinical and Translational Science
|
August 10, 2021
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
Holger Scheible, Martin Dyroff, Annick Seithel-Keuth, et al.
Clinical and Translational Science
|
February 27, 2024
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma
Ping Hu, Haiqing Isaac Dai, James Bourdage, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 12, 2010
Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis
Jonathan W Jones, Nobuhiko Kayagaki, Petr Broz, et al.
Clinical Pharmacology in Drug Development
|
May 29, 2025
Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [<sup>14</sup>C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study
Jayaprakasam Bolleddula, Holger Scheible, Florian Huber, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Clinical and Translational Science
|
June 20, 2022
Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies
Jayaprakasam Bolleddula, Sathej Gopalakrishnan, Ping Hu, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists
|
March 29, 2014
Mesodermal Fgf10b cooperates with other fibroblast growth factors during induction of otic and epibranchial placodes in zebrafish
Kirstin Maulding, Mahesh S Padanad, Jennifer Dong, et al.
Journal of Medical Education and Curricular Development
|
December 30, 2025
Assessing Clinical Integration of Point-of-Care Ultrasound With an Objective Structured Clinical Examination
N Caroline Srisarajivakul-Klein, Jennifer Dong, Aron Mednick, et al.
Cancer Chemotherapy and Pharmacology
|
June 30, 2022
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
Wenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, et al.
Clinical and Translational Science
|
October 24, 2024
Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler
Hong Lu, Lena Klopp-Schulze, Jatinder Kaur Mukker, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
October 26, 2023
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective
Holger Scheible, Hanno Schieferstein, Ralf Schmidt, et al.
Clinical and Translational Science
|
August 10, 2021
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
Holger Scheible, Martin Dyroff, Annick Seithel-Keuth, et al.
Clinical and Translational Science
|
February 27, 2024
Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma
Ping Hu, Haiqing Isaac Dai, James Bourdage, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 12, 2010
Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis
Jonathan W Jones, Nobuhiko Kayagaki, Petr Broz, et al.
Clinical Pharmacology in Drug Development
|
May 29, 2025
Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [<sup>14</sup>C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study
Jayaprakasam Bolleddula, Holger Scheible, Florian Huber, et al.
Page
of 2